Pyridostigmine Bromide ( DrugBank: Pyridostigmine )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
3	脊髄性筋萎縮症	2
6	パーキンソン病	3
256	筋型糖原病	1

3. 脊髄性筋萎縮症

臨床試験数 : 237 / 薬物数 : 123 - (DrugBank : 29) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 75

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-004369-34-NL (EUCTR)	22/04/2015	03/11/2014	SPACE trial SMA and Pyridostigmine in Adults and Children; Experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4	SPACE trial SMA and Pyridostigmine in Adults and Children; Efficacy trial Phase II, mono-center, doubleblind, placebo-controlled, crossover trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2, 3 and 4 - SPACE trial	Proximal spinal muscular atrophy (SMA) is characterized by weakness of predominantly axial and proximal muscle groups and is caused by homozygous deletion of the survival motor neuron 1 (SMN1)-gene. There are 4 SMA types (type 1-4), with a descending order of severity. Age at onset and achieved motor milestones are the characteristics to define severity. Treatment of SMA is exclusively supportive. MedDRA version: 17.1;Level: LLT;Classification code 10068209;Term: Spinal muscular atrophy adult onset;System Organ Class: 100000004850 MedDRA version: 17.1;Classification code 10051203;Term: Spinal muscular atrophy congenital;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: pyridostigmine bromide Product Name: Mestinon Product Code: RVG 03820	Universtiy Medical Center Utrecht	NULL	Not Recruiting			Female: yes Male: yes	45	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Netherlands
2	NCT02227823 (ClinicalTrials.gov)	July 2014	20/8/2014	Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3	Safety and Efficacy Study of Anti-cholinesterase Therapy on the Motor Functions in Patients With Spinal Muscular Atrophy Type 3.	Spinal Muscular Atrophy Type 3	Drug: Pyridostigmine Bromide	Centre Hospitalier Régional de la Citadelle	NULL	Recruiting	6 Years	N/A	Both	20	Phase 2	Belgium

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05603715 (ClinicalTrials.gov)	August 10, 2022	12/9/2022	Pyridostigmine for the Treatment of Constipation in Parkinson Disease	Pyridostigmine for the Treatment of Constipation in Parkinson Disease	Parkinson Disease;Constipation	Drug: Pyridostigmine Bromide	University of Vermont Medical Center	NULL	Recruiting	18 Years	N/A	All	16	Phase 2	United States
2	EUCTR2012-000122-21-DK (EUCTR)	10/08/2012	07/06/2012	Improving the blood pressure regulating system in patients with parkinsons disease	Acethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons disease	Ortostatic hypotension in patients with Parkinsons disease MedDRA version: 14.1;Level: PT;Classification code 10031127;Term: Orthostatic hypotension;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]	Trade Name: Mestinon Product Name: Mestinon INN or Proposed INN: PYRIDOSTIGMINE BROMIDE Other descriptive name: Mestinon	Department of Neurology, Roskilde Hospital	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 2	Denmark
3	NCT01993680 (ClinicalTrials.gov)	June 2012	27/4/2012	Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment	A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's Disease	Autonomic Disturbances in Parkinson's Disease	Drug: Pyridostigmine bromide;Drug: fludrocortisone	Christian Baumann	NULL	Completed	50 Years	80 Years	All	18	Phase 2	Switzerland

256. 筋型糖原病

臨床試験数 : 180 / 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02357225 (ClinicalTrials.gov)	August 2015	23/1/2015	A Pilot Study of Pyridostigmine in Pompe Disease	Evaluation of Respiratory and Skeletal Muscle Functions in Response to Acetylcholinesterase Inhibitors in Pompe Disease	Pompe Disease	Drug: Pyridostigmine Bromide	University of Florida	NULL	Terminated	8 Years	60 Years	All	2	Early Phase 1	United States

先頭へ